White House bats down speculation that Trump got access to Eli Lilly obesity drug for ‘compassionate use’
Summary
White House officials denied reports that President Donald Trump received the weight-loss drug retatrutide through the FDA's compassionate use program. Retatrutide is made by the company Eli Lilly but is not yet approved by the FDA.Key Facts
- The drug retatrutide is designed to help with obesity and is made by Eli Lilly.
- Retatrutide is not yet approved by the FDA for general use.
- The FDA has a compassionate use program that allows certain unapproved drugs to be given to people in special cases.
- A report said President Trump got access to retatrutide through this program.
- The White House denied this report, saying it is not true.
- The story was clarified on a Tuesday by White House officials.
- No confirmation was given about who accessed the drug through the program.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.